Informace o publikaci

Statins in oncological research: From experimental studies to clinical practice

Logo poskytovatele
Logo poskytovatele
Autoři

KUBATKA Peter KRUŽLIAK Peter ROTREKL Vladimír JELÍNKOVÁ Šárka MLADOSIEVICOVA Beata

Rok publikování 2014
Druh Článek v odborném periodiku
Časopis / Zdroj Critical Reviews in Oncology/Hematology
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Doi http://dx.doi.org/10.1016/j.critrevonc.2014.08.002
Obor Onkologie a hematologie
Klíčová slova Anti-tumor properties; Cancer risk reduction; Cancer therapy; Carcinogenesis; Chemoprevention; Statins
Popis Statins, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors are commonly used drugs in the treatment of dyslipidemias, primarily raised cholesterol. Recently, many epidemiological and preclinical studies pointed to anti-tumor properties of statins, including anti-proliferative activities, apoptosis, decreased angiogenesis and metastasis. These processes play an important role in carcinogenesis and, therefore, the role of statins in cancer disease is being seriously discussed among oncologists. Anti-neoplastic properties of statins combined with an acceptable toxicity profile in the majority of individuals support their further development as anti-tumor drugs.The mechanism of action, current preclinical studies and clinical efficacy of statins are reviewed in this paper. Moreover, promising results have been reported regarding the statins' efficacy in some cancer types, especially in esophageal and colorectal cancers, and hepatocellular carcinoma. Statins' hepatotoxicity has traditionally represented an obstacle to the prescription of this class of drugs and this issue is also discussed in this review.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info